Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Erganeo
Paris, Franceerganeo.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Erganeo specializes in identifying disruptive deep tech innovations from public research institutions in France and accelerating their translation into commercial applications. It has enabled the creation or growth of several biotech startups with promising preclinical results—such as first-in-class small molecules targeting CXCR4 for autoimmune diseases with demonstrated proof-of-concept in animal models—and gene therapies for neurodegenerative disorders. Some projects have advanced toward early clinical development through its support.
- Therapeutic areas
- NeurologyOncologyOtherImmunologyRheumatology
- Modalities
- Small moleculeGene therapyExosome-based therapyMedical deviceVaccineTissue engineeringImplantable devicesBiologicExtracellular vesiclesRegenerative medicine tools
- Industry
- Investors
02
Partnerships
CNRSUniversité Paris Citéventure funds
Beyond the preview
Go deeper on Erganeo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Erganeo.